Department of Pharmaceutics (J.J., S.S., A.R.T., N.I.), Department of and Environmental and Occupational Health Sciences (R.P., B.C., K.S.G., T.M.B.), Center on Human Development and Disability (K.S.G., T.M.B.), and Infant Primate Research Laboratory, Washington National Primate Research Center, University of Washington, Seattle, Washington (K.S.G., T.M.B.).
Department of Pharmaceutics (J.J., S.S., A.R.T., N.I.), Department of and Environmental and Occupational Health Sciences (R.P., B.C., K.S.G., T.M.B.), Center on Human Development and Disability (K.S.G., T.M.B.), and Infant Primate Research Laboratory, Washington National Primate Research Center, University of Washington, Seattle, Washington (K.S.G., T.M.B.)
Drug Metab Dispos. 2018 Feb;46(2):155-165. doi: 10.1124/dmd.117.078485. Epub 2017 Nov 17.
Domoic acid (DA), a neurotoxin, is produced by marine algae and has caused toxications worldwide in animals and humans. However, the toxicokinetics of DA have not been fully evaluated, and information is missing on the disposition of DA following oral exposures at doses that are considered safe for human consumption. In this study, toxicokinetics of DA were investigated in cynomolgus monkeys following single doses of 5 g/kg DA intravenously, 0.075 mg/kg DA orally, and 0.15 mg/kg DA orally. After intravenous dosing, DA had a systemic clearance of 124 ± 71 (ml/h)/kg, volume of distribution at steady state of 131 ± 71 ml/kg and elimination half-life of 1.2 ± 1.1 hours. However, following oral dosing, the average terminal half-life of DA was 11.3 ± 2.4 hours, indicating that DA disposition follows flip-flop kinetics with slow, rate-limiting absorption. The absorption of DA was low after oral dosing with absolute bioavailability of 6% ± 4%. The renal clearance of DA was variable [21-152 (ml/h)/kg] with 42% ± 11% of the intravenous DA dose recovered in urine. A physiologically based pharmacokinetic model was developed for DA in monkeys and humans that replicated the flip-flop kinetics observed after oral administration and allowed simulation of urinary excretion and brain and kidney distribution of DA following intravenous and oral dosing. This study is the first to characterize DA disposition at exposure levels close to the current estimated tolerable daily intake and to mechanistically model DA disposition in a model species, providing important information of the toxicokinetics of DA for human safety assessment.
中文译文:
标题: 一种神经毒素(DA)在动物和人类中引起了全球范围内的中毒
摘要: 一种神经毒素(DA)在动物和人类中引起了全球范围内的中毒。然而,DA 的毒代动力学尚未得到充分评估,并且对于在被认为是人类可接受的摄入量下口服暴露后 DA 的处置情况,信息缺失。在这项研究中,在恒河猴中研究了单次静脉内给予 5 g/kg DA、口服给予 0.075 mg/kg DA 和口服给予 0.15 mg/kg DA 后 DA 的毒代动力学。静脉内给药后,DA 的全身清除率为 124 ± 71(ml/h)/kg,稳态分布容积为 131 ± 71 ml/kg,消除半衰期为 1.2 ± 1.1 小时。然而,口服给药后,DA 的平均终末半衰期为 11.3 ± 2.4 小时,表明 DA 的处置遵循翻转动力学,吸收缓慢且受到速率限制。口服给药后 DA 的吸收程度较低,绝对生物利用度为 6%±4%。DA 的肾清除率变化较大[21-152(ml/h)/kg],静脉内给予的 DA 剂量中有 42%±11%在尿液中回收。在猴子和人类中建立了 DA 的基于生理学的药代动力学模型,该模型复制了口服给药后观察到的翻转动力学,并允许模拟静脉内和口服给药后 DA 在尿液中的排泄以及脑和肾中的分布。这项研究首次在接近当前估计可耐受每日摄入量的暴露水平下描述了 DA 的处置,并在模型物种中对 DA 的处置进行了机制建模,为人类安全评估提供了有关 DA 毒代动力学的重要信息。